We are live on ! Find out more
SEEL

Seelos Therapeutics, Inc. Common Stock

Delisted

SEEL was delisted on the 15th of October, 2024.

82 hedge funds and large institutions have $67.8M invested in Seelos Therapeutics, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 30 increasing their positions, 17 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,950% more call options, than puts

Call options by funds: $4.51M | Put options by funds: $220K

76% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 17

14% less funds holding

Funds holding: 9582 (-13)

31% less capital invested

Capital invested by funds: $98.2M → $67.8M (-$30.4M)

63% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 19

Holders
82
Holders Change
-13
Holders Change %
-13.68%
% of All Funds
1.26%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
7
Increased
30
Reduced
17
Closed
19
Calls
$4.51M
Puts
$220K
Net Calls
+$4.29M
Net Calls Change
+$2.86M

SEEL Hedge Fund Activity: Q4 2021 in Review

82 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Seelos Therapeutics, Inc. Common Stock (SEEL) for Q4 2021, worth a combined $67.8M — down 31% from $98.2M a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of SEEL and 7 opened new positions — a net loss of 12 holders — while 17 trimmed existing stakes and 30 added.

The largest buyer was Group One Trading, opening a new position worth an estimated $1.94M. The largest seller was Millennium Management, cutting an estimated $1.19M.

  • 82 institutional investors held Seelos Therapeutics, Inc. Common Stock (SEEL) as of Q4 2021, down from 95 in Q3 2021.
  • Funds reported $67.8M of Seelos Therapeutics, Inc. Common Stock stock for Q4 2021, down 31% quarter-over-quarter.
  • 7 funds opened new Seelos Therapeutics, Inc. Common Stock positions in Q4 2021 and 19 closed out, a net change of -12 holders.
  • The largest Seelos Therapeutics, Inc. Common Stock buyer in Q4 2021 was Group One Trading, an estimated $1.94M added.
  • The largest Seelos Therapeutics, Inc. Common Stock seller in Q4 2021 was Millennium Management, an estimated $1.19M sold.

Based on aggregated 13F filings for Q4 2021.